Sofovir-C is the brand name for sofosbuvir, a nucleotide analog inhibitor of HCV NS5B polymerase. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.

Sofovir-C efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection. Sofosbuvir, the first USFDA approved an oral drug which opens the new era in the treatment of Chronic Hepatitis C and overcomes the limitation of Peginterferon-α therapy with excellent clinical success.

Sofovir-C is a breakthrough oral therapy for Hepatitis C which is safe, effective and compliant and has numerous benefits for treating Hepatitis C patients.

• Highly effective in treating CHC with other Direct Acting Antivirals
• Better tolerability profile than Interferon-based therapy
• Saves treatment than Interferon-based therapy
• Short duration of treatment than Interferon-based therapy

  Full Prescribing Information